ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Mesoblast Limited Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – MESO
10 nov. 2020 12h22 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and...
Equillium to Present at Investor Conferences in November 2020
10 nov. 2020 08h35 HE
|
Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
04 nov. 2020 08h35 HE
|
Equillium
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
03 sept. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium Announces Pricing of Public Offering of Common Stock
13 août 2020 21h42 HE
|
Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
12 août 2020 08h37 HE
|
Equillium
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
30 mars 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
13 févr. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
12 déc. 2019 07h00 HE
|
Equillium; Biocon Ltd
LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop...